Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Artiva Biotherapeutics, Inc.ARTV · Entity 5404 | Chief Medical Officer | February 26, 2025 | February 28, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Artiva Biotherapeutics, Inc.
Report date February 26, 2025 · Filed February 28, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 80,000 |
Reported balance
After 2025-02-26 transaction · row 1
1 source rowRow 1 · 2025-02-26 · Grant · Acquired 60,000 · Balance 80,000 F1: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2025 Filed Feb 28, 2025 22:15 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006036 · form4-02282025_050209.xml · nonDerivative · entry 1 Graef Thorsten · CIK 0001581192 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 20:15 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-023363 · form4-09132024_040909.xml · nonDerivative · entry 1 Graef Thorsten · CIK 0001581192 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.